SOURCE: Realm Therapeutics

October 16, 2017 02:00 ET

Realm Therapeutics to Present at the 2017 BIO Investor Forum

MALVERN, PA--(Marketwired - Oct 16, 2017) - Realm Therapeutics PLC (AIM: RLM)


Realm Therapeutics plc
("Realm Therapeutics", "Realm" or the "Company")

Realm Therapeutics to Present at the 2017 BIO Investor Forum

Update on atopic dermatitis and allergic conjunctivitis clinical trials and recent financing

16 October 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the 2017 BIO Investor Forum on Wednesday, 18 October at 9:45 AM at the Westin St. Francis Hotel in San Francisco, CA.

Mr. Martin will review the Company's two lead drug development programmes - PR022 for Atopic Dermatitis and PR013 for Allergic Conjunctivitis, as well as its recent raise of £19.3 million ($26 million) through a private placement with new and existing investors, including several healthcare specialist funds based in the US and the UK.

Realm recently announced U.S. Food and Drug Administration (FDA) clearance to proceed into a Phase II clinical trial for PR013 as a novel treatment for Allergic Conjunctivitis and which is expected to commence by the end of the year. Additionally, the Company remains on track to initiate a Phase II trial for PR022 for Atopic Dermatitis by end of the year as well. The recent financing will be used to advance both these programmes and to conduct a Phase II proof of concept study in Acne Vulgaris.

Realm Therapeutics plc +44 (0) 20 3727 1000
Alex Martin, Chief Executive Officer  
Marella Thorell, Chief Financial Officer and Chief Operating Officer  
FTI Consulting +44 (0) 20 3727 1000
Simon Conway / Mo Noonan  
N+1 Singer (Nominated Adviser and Broker) +44 (0) 20 7496 3000
Aubrey Powell / Lauren Kettle  

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology. 

Forward looking statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS
The company news service from the London Stock Exchange


Contact Information